The Compound Group
Volume 01 · Est. 2026

We build the healthcompanies that should exist.Then we quietly acquire the ones that already do.

A consumer biotech media studio. GLP-1 to neuroscience. Supplements to pet health. We build what we'd want to use. We acquire what's already working.

¹Footnoted as in every stat has a source, every methodology is public, every ranking shows our work — the standard we'd want applied to anything we'd use ourselves.
Scroll · Portfolio below
§Portfolio — active and forthcoming
🔒glp1picks.com
The Pricing Index
34 providers · Updated 2026-09-10
Vol. IV
Issue 04
Editor's Top Pick
Fridays
$117/mo · All-in · No hidden fees
8.7
of 10
02bmiMD$159/mo8
03Sesame Care$99/mo7.9
04Direct Meds GLP-1$297/mo7.9
05DudeMeds$149/mo7.8
Methodology publishedRead the full index →
ILiveBuilt in-house

GLP-1 Picks

Compare GLP-1 partner programs by cost, care and transparency.

We review 34 approved GLP-1 partner programs using a published scoring methodology. Reviews cover full costs, clinical care and pricing transparency. Partnership determines which providers appear; it does not determine their scores. The scoring methodology is published in full, the affiliate relationships are disclosed on every page, and the rankings follow directly from the methodology. When we earn a commission on a visit, the page you're reading says so.

Type
Comparison site
Revenue
Affiliate
Since
2026
Visit glp1picks.com
hrtpicks.com
HRT·Picks
Menopause HRTMen’s TRT

Menopause HRT · Approved partners

Find your online HRT price in 30 seconds

Compare treatment, delivery method and cost.

Approved partner price finder

Hormone

Estradiol ⌄

Delivery

Any route ⌄

Compare providers →Costs & insurance →
IILiveBuilt in-house

HRT Picks

Compare approved hormone-care partners with verified prices and published scoring.

HRT Picks compares approved affiliate partners through separate menopause HRT and men's TRT journeys. Each includes a treatment finder, costs, insurance guidance and provider reviews. Approval determines which providers enter the shopping catalog; the published methodology determines scores and rank within that set. Prices carry billing terms and verification dates, and transparency grades show what each provider discloses before intake.

Type
Comparison site
Revenue
Affiliate
Since
2026
Visit hrtpicks.com
glp1pets.com

Cats first · Dogs next

GLP-1 weight loss drugs for pets are in trials now.

No GLP-1 drug is FDA-approved for weight loss in dogs or cats.

Tell me when the status changes

Need help now? Work out your dog’s portions & food cost

Free tools · Trial status updates

IIILiveBuilt in-house

GLP-1 Pets

Independent pet GLP-1 trial coverage and practical weight-management tools for owners.

Sixty-one percent of US cats and fifty-nine percent of US dogs are overweight or obese (APOP). The pharmaceutical answer is still in trials. Okava's MEOW-1 study of an exenatide-releasing implant in cats reads out Summer 2027, and Akston Biosciences is running a once-weekly injection at Cornell with a readout window of H2 2026. Neither is approved and neither is something an owner can buy. We track trial milestones, regulatory actions and pricing signals. Owners can also use body-condition tools and a free dog food calculator to turn a veterinary calorie target into portions, daily cost and a printable summary.

Type
Authority site
Revenue
Affiliate (post-launch)
Since
2026
Visit glp1pets.com
Titrate
Peptide & GLP-1
Reconstitution, doses,
stacks, side effects.
One app. Every unit.
iOS first
Launching 2026
9:41
Monday, April 14
Today's stack
Tirzepatide
5.0 mg
Due today · Left abdomen
BPC-157
250 mcg
✓ Logged
M
T
W
T
F
S
S
Reconstitution
10 mg vial · 2 mL BAC · 0.25 mL per 1.25 mg
Weight
184.2lb
−12.4
IVLiveBuilt in-house

Titrate

A peptide and GLP-1 tracker built around the decisions a patient keeps making — dose, reconstitution, stack, refill, program.

The core logging works the way these apps should: doses, weight trends, side effects, injection-site rotation. The decision-support layer is where Titrate departs from the category. Reconstitution calculators with a unit toggle the category has been missing. Multi-compound stacking past the three-peptide ceiling most apps cap at. And as programs update their pricing structures, formularies, and dose-escalation policies, the app surfaces the ones that continue to fit your situation — so the next refill is a deliberate choice. Now shipping on the App Store; the marketing site at titrate.health is the way in.

Type
iOS app
Revenue
Subscription + affiliate
Since
May 2026
Visit titrate.health
bestpeptideforthat.com/providers
BPFT↗Best Peptide
For That
Providers · Compounds · Tools

The product & provider board

Know the product.
Understand
the price.

Compare the exact product, format and published conditions before choosing a provider.

Explore the board ↓

A clearer comparison

Read the details.
See the gaps.

01Match the product and format↗
02Read the financial conditions↗
03Check what remains unknown↗
Product · Source · Price conditionsPayment timeline ↗
VLiveBuilt in-house

Best Peptide For That

Compare the evidence, the product and the price.

Best Peptide for That brings 46 compounds into a goal-led directory that includes GLP-1. Readers can compare compound evidence separately from products and providers, inspect dated advertised prices and missing terms, and calculate a plan's payment commitment. The provider board spans the wider catalog, including adjacent products clearly identified as such. An overall evidence grade is not a claim that a compound is the best treatment for every goal. Affiliate activation remains separate from the published evidence and pricing records.

Type
Comparison directory
Revenue
Affiliate (activation pending)
Since
2026
Visit bestpeptideforthat.com
longevityranked.com
Longevity RankedNAD+ & sermorelin

Longevity care, compared

Compare NAD+ and sermorelin providers, prices and plans.

The product. The payment terms. The questions to ask.

NAD+

Compare providers

Sermorelin

See prices and plans

Longevity Ranked. Separate treatment categories, clear provider comparisons.
VILiveBuilt in-house

Longevity Ranked

Compare NAD+ and sermorelin providers, prices and plans.

Longevity Ranked helps readers compare longevity-related care, starting with NAD+ and sermorelin. Separate treatment guides, provider reviews and price comparisons make the product, payment schedule and missing terms visible before a reader visits a provider. These are distinct categories, not interchangeable treatments. Commercial arrangements remain separate from the presentation of evidence and costs.

Type
Comparison site
Focus
NAD+ & sermorelin
Since
2026
Visit longevityranked.com
🔒revolume.app
RevolumeA Compound product
For Ozempic · Wegovy · Mounjaro · Zepbound
You lost the weight.
Don't lose your face.
Track facial volume changes on GLP-1. A skin scan in 60 seconds.
Join the waitlist
ComingiPhone
Cited: Vanderbilt Facial Volume Study, JCD 2026, ASDS.
Cheek volume
Jawline laxity
Marker map
VIIIn developmentBuilt in-house

Revolume

The skin scan built for GLP-1 — because the weight comes off, and the face follows.

Sixty-five percent of patients on semaglutide, tirzepatide, or compounded GLP-1s experience facial volume loss within their first six months on the medication. Revolume is a private, on-device skin scan that measures the markers specific to post-rapid-weight-loss skin, volume and jawline definition and nasolabial depth and laxity, then routes the user to the routine, the telehealth prescription, or the in-clinic procedure that actually fits the stage they're at.

Type
Web scan + iOS app
Revenue
Affiliate + procedure referral
Launch
2026
Visit revolume.app
§§Specialist sites in development

Shared comparison tools. Different buying decisions.

Following Longevity Ranked, these specialist websites have working scaffolds and content plans. Each will focus on its audience's products, price comparisons and evidence questions. BPFT continues to cover the full peptide catalog and GLP-1 alongside them.

Names are provisional. These comparison sites are not publicly launched, and no affiliate earnings are implied. Neuroplasticity Lab remains a separate planned project.

  • 01
    Hair Index
    Hair-care plan and product comparisons, separating prescription care from cosmetic scalp products and their refill costs.
    Hair careScaffold
  • 02
    Desire Index
    The existing sexual-health project, extended with product-specific care, access and cost comparisons for distinct concerns.
    Sexual healthScaffold
  • 03
    Skin Index
    Topical peptide skincare comparisons organized around product labels, bottle size, delivered cost and cosmetic claims.
    Skin & copper peptidesScaffold
  • 04
    Recovery Index
    Recovery-related care and product comparisons, with research evidence separated from verified commercial options.
    Recovery & muscleScaffold
  • 05
    Neuroscience Index
    Cognitive product labels, evidence and recurring costs, keeping supplements and investigational compounds distinct.
    Cognitive productsScaffold
  • 06
    Sleep Index
    Sleep-related product and service comparisons, covering purchase terms, evidence and trial or return conditions.
    Sleep products & careScaffold
  • 07
    Supplement Index
    Supplement comparisons based on disclosed ingredients, container sizes, testing information and purchase terms.
    Nutritional productsScaffold
  • 08
    Neuroplasticity Lab
    A separate planned comparison project for cognitive apps, devices and training tools. It complements Neuroscience Index rather than duplicating its supplement scope.
    Training & toolsPlanned
◉The map · How the properties connect

A portfolio is a graph. This is where the edges are.

Each circle is a product or a public asset the studio maintains. The edges describe audience overlap, shared methodology, or infrastructure that recurs across categories. Hover a node to trace its relationships — or grab one and rearrange the map yourself.

Hover or tap a node
ParentLive productIn developmentPlannedPublic resourceAudience feedShared resource

Four properties are live, one more in development. Four more come online across 2026 and 2027. As they do, the graph densifies — a shared methodology, shared datasets, and an audience that overlaps more than any one product suggests on its own. The compounding, when it works, lives in the edges — in how the nodes connect.

The ledger

Every number, including the bad ones.

Revenue and earnings per partner. Search performance on every property, and the one property that is not connected yet. Forecast accuracy with the wrong calls written up in the same detail as the right ones. What broke, and how many days it ran green while broken. What we published and whether search ever found it. And the costs nobody here is tracking, listed as untracked rather than left off.

It lives on one page because a number that appears in two places eventually disagrees with itself. This site used to state portfolio scale in four places on four different dates. Now it states it in one.

  • Revenue and conversions
  • Search performance
  • Forecast accuracy
  • Work-order throughput
  • What broke
  • Content published, and whether it ranked
  • AI citation share
  • Spend
Read the ledger
Generated 2026-09-15
∞The operating system

A portfolio that learns in public.

Each property has its own audience and subject matter. The operating pattern is shared: find a real decision, make the answer more useful, measure the result, and feed the evidence into the next pass.

Automation handles repeatable observation and maintenance. People retain control of standards, editorial conclusions, and consequential changes.

Inspect the operating canvas
01

Signal

Search demand, reader questions, changing prices, partner status, and market events enter as evidence rather than instinct.

02

Decision

The system turns evidence into a small queue. Standards and editorial judgment decide what is allowed to change.

03

Publish

Useful comparisons, tools, and routes meet a specific decision. Each property adapts the engine to its own audience.

04

Learn

Traffic, engagement, conversion, and failures return to the record. The next cycle starts with what actually happened.

Evidence inHuman rulesUseful actionRecorded outcome
‡Pricing data · Read from the index on 2026-09-10

The price a program leads with, plotted against the top of its own price list.

Horizontal is the headline monthly price. Vertical is the highest monthly tier the same program publishes anywhere in its own pricing table, across every drug and every dose it sells. The dashed diagonal is where the two are equal. Both axes are logarithmic, because the spread runs from double figures to four. Hover a dot for the pair.

A program sitting high is not necessarily overcharging. Usually it carries brand-name Wegovy or Zepbound at an undiscounted cash rate alongside a compounded product at a fraction of it. The distance is the reason one advertised number tells you so little on its own.

Highest published tier ↑
$50$100$250$500$1000$2000
$2000$1000$500$250$100$50
Headline monthly price →
Headline price is the top of the listThe list goes higher than the headlineParity line
Programs plotted
34
Out of the 34 programs in the index on glp1picks.com
One rate only
1
Programs whose published list tops out at the price they lead with
Median multiple
2.0×
The typical program's highest tier, as a multiple of the price it leads with
Widest spread
Fridays $117 to $1828
Both figures come off the same program's own page. The low one buys a compounded product, the high one buys the brand at an undiscounted cash rate.
Publishes no tier table
0
. Left off the chart rather than placed on the parity line, because publishing no tier is not the same fact as publishing one.
ΩHow we operate

Research has a shape. This is how ours gets organized.

●Published methodology
●Named medical reviewers
●Disclosed affiliate relationships
●Versioned recommendations
●Peer-reviewed sources
●Verified pharmacy licenses
●Audited side-effect data
●Tracked ongoing pricing
●Pet-health research
●Mapped search intent
●Quarterly content review
●Public changelog
●Published methodology
●Named medical reviewers
●Disclosed affiliate relationships
●Versioned recommendations
●Peer-reviewed sources
●Verified pharmacy licenses
●Audited side-effect data
●Tracked ongoing pricing
●Pet-health research
●Mapped search intent
●Quarterly content review
●Public changelog
01Pillar · databases

Databases

Every ranking is grounded in data we maintain ourselves, in one file per property that everything else reads from.

Pricing, dosing schedules, FDA alerts, state-level Medicaid coverage, and the terms of our affiliate partnerships live in one structured file per property. Every page reads from it rather than restating it, including this one: the figures on this site are generated out of those files and carry the date they were read. When something shifts, a new formulation or a revised policy or a price change, the one file changes and every page follows.

97
Provider and compound records maintained across the GLP-1, hormone and peptide indices
✧Intelligence layer

Research is the whole game.

Barque is the protocol we lean on for it. Curiosity paired with a dataset far larger than any one mind can hold — cross-signal fusion, five-agent scenarios, Brier-scored forecasts. It tells us what to build, what to skip, and when the window opens.

Informs every page at GLP-1 Picks, every feature in GLP-1 Tracker, and the next verticals we're scouting.

Backtests resolved
4
4 of 4 direction-correct
Average Brier score
0.066
Lower is better · below 0.10 is strong calibration
Live forecasts
4
Currently pending, with public resolution dates
❝From our methodology
Show the work, and keep showing it — as the evidence changes, so should the conclusion.
†Operating principles

We started by asking ourselves the same questions the sites now answer. What does a GLP-1 program actually cost over a year of use. Which supplements have real research behind them. How dose escalation works in practice, not in the marketing copy.

The answers took more work than we expected. So we kept the notes. The notes became databases. The databases became sites.

Research before opinion. Methodology before recommendation. Infrastructure that compounds across categories. The work is the work.

Four commitments

The four operating constraints each property in the portfolio is built around, regardless of category or stage.

Crystalline molecular network rendered in warm light

Research · Structured and maintained

I
Transparency

The scoring methodology for every ranking is published in detail on every site we run. Every affiliate relationship is disclosed on the pages where it's relevant. And we report pricing as the ongoing monthly cost a typical patient pays over a full year of use — the number that matters once the introductory period ends.

II
Specificity

Our content names the specific program, quotes the specific cost, and describes the specific trade-off — which is what lets a reader actually weigh one option against another. The reader who comes back for the next question is worth more than a reader who clicks once on a generic superlative.

III
Compounding

Each property in the portfolio extends the same research discipline into an adjacent category. The audience that trusts our GLP-1 work is the same audience looking for supplement guidance. The database infrastructure built for one transfers directly to the next. Pet health broadens the methodology to a parallel customer base; the neuroscience work reads to a different reader entirely. The underlying process travels.

IV
Patience

We build for ten years — content that ages well, data that's audited continuously, partner relationships that hold. If an acquisition is part of the story, it's because the work stands up to scrutiny the way we'd want our own work scrutinized.